believed that TAFI activation by thrombin/ thrombomodulin complex occurs on endothelial surface adjacent to the hemostatic plug and protects the outside of the fibrin matrix from fibrinolysis, whereas TAFI activation by thrombin alone takes place within the hemostatic plug and serves to down-regulate fibrinolysis induced by tPA incorporated into the fibrin plug (13) . Under the latter condition, antifibrinolytic amounts of TAFIa are generated only if high amounts of thrombin are formed, likely via a factor nine (FIX)-dependent feedback mechanism (13) , and any impairment of TAFIa formation will translate in highly accelerated fibrinolysis because plasmin generated within a fibrin clot has a much higher impact on fibrinolysis than plasmin generated at the clot surface (14, 15) .
The potential physiological role of TAFI in the fibrinolytic process is underscored by numerous in vitro and in vivo data (5, 10, (16) (17) (18) (19) , and evidence is accumulating suggesting that alterations in the TAFI pathway, either because of derangements in the TAFI-activating capacity or because of changes in TAFI levels, may contribute to bleeding or thrombosis (20) (21) (22) . There is no previously reported study about TAFI activity and thrombocytosis. Our study was thus undertaken to evaluate the levels of TAFI activity and also its relationship with prothrombin time (PT), active partial thromboplastin time (aPTT), D-dimer, and fibrinogen in a group of patients affected with thrombocytemia as compared with a group of healthy controls.
MATERIALS AND METHODS

Patients
Twenty-one patients (10 women and 11 men) aged 56.19±18.98 years, affected with clonal thrombocytosis (Group 1); 21 patients (15 women and 6 men) aged 52.48±15.06 years, affected with secondary thrombocytosis (Group 2); and 21 healthy controls (13 women and 8 men) aged 55.38±11.06 years (Group 3), with normal platelet counts, were investigated. Informed consent was obtained from each subject after the explanation of the study protocol. In the first group, 6 patients (28.6%) had chronic myelogeneous leukemia, 2 (9.5%) had polycythemia vera, 11 (52.4%) had essential thrombocythemia and 2 (9.5%) had osteomyelofibrosis. In the second group all of the patients had iron deficiency anemia.
In each subject the following tests were carried out: hemoglobin, hematocrit, leukocyte, platelet count, mean platelet volume, mean corpucular volume, TAFI activity, PT, aPTT, fibrinogen and D-dimer concentrations. No patient had clinical signs of thrombosis for at least 3 months before the study, and no patient or control subject had received any drug known to affect platelet and fibrinolytic tests or had been smoking.
Samples
Blood was collected from an antecubital vein without stasis between 8.00 and 9.00 A.M., after an overnight fast and supine rest. Nine mL of each sample was transferred to polpropylene tubes containing 104 mM sodium citrate (volume ratio 9+1). After centrifugation at 3000 × g for 15 minutes, the supernatant plasma was stored at -80°C and tested within 1 month. Blood clotting tests were performed on fresh plasma samples.
Prothrombin time and partial thromboplastin time were assesed with a coagulometer, and fibrinojen levels with a nephelometer. D-Dimer levels were studied with enzyme-linked fluorescent assay (VIDAS D-Dimer New [DD2], bioMérieux sa, France). Plasma TAFI activity was measured by a chromogenic assay (Pefakit TAFI, Pentapharm Ltd, Basel, Switzerland). Complete blood counts were measured with Coulter MaxM (Philadelphia, California), and the upper limit of normal blood platelet count range was determined as 150-450 × 10 9 /L.
Statistical Analysis
Nonparametric and Mann-Whitney U tests were used for statistical analysis. A p value <0.05 was assumed as significant. Tables 1-3 . Hemoglobin (13.33±3.77 g/dL), hematocrit values (39.75±10.64%), and mean corpuscular volume (79.12±10.64 µ 3 ) were significantly higher in the first group than in the second group (9.13±2.47 g/dL, 28.65±6.42%, and 68.03±11.45 µ 3 , respectively) (p<0.05) ( Table 1) .
RESULTS
Our results are summarized in
Platelet and leukocyte counts were significantly higher in the clonal thrombocytosis group (869.19±344.61 × 10 9 /L and 44.89±63.67 × 10 9 /L, respectively) than in both the reactive thrombocytosis (568.16±125.17 × 10 9 /L and 8.89±2.71 × 10 9 /L, respectively) and control groups (223.28±16.48 × 10 9 /L and 8.20±2.80 × 10 9 /L, respectively) and also higher in the reactive thrombocytosis group than in controls (p<0.05) (Tables 1-3) . Activated partial thromboplastin time and protrombin times were lower in the first group (29.68±8.00 sec and 12.46±2.22 sec, respectively) than in the second group (30.9±2.56 sec and 13.27±0.93 sec, respectively) (p<0.05), and in the control group (30.15±10.14 sec and 13.75±1.75 sec, respectively) (p>0.05) (Tables 1-3 ). Both fibrinogen and D-dimer values were higher in the first group (3.24±0.73 g/L and 208.05±124.32 ng/mL, respectively) and in the second group (3.63±1.03 g/L and 214.48±133.60 ng/mL, respectively), than in controls (172.10±19.87 and 2.61±0.82 g/L, respectively) (p<0.05 and p<0.05, respectively) (Tables 1-3 ).
TAFI activity was 171.53±34.35 µg/mL in the first group, 147.64±33.30 µg/mL in the second group and 145.47±28.36 µg/mL in the control group. TAFI activity was significantly higher in the first group than in the other two groups (p<0.05) (Tables 1-3) .
DISCUSSION
Interacting and counteracting mechanisms of coagulation and fibrinolysis bring out different states of hemostatic imbalance in accordance with type and extent of accompanying diseases. In myeloproliferative disorders, bleeding and 3,23,24) . The most commonly accepted causes contributing to thrombotic manifestations are increase in blood viscosity and thrombocytosis (1) . In our study, levels of fibrinogen and Ddimer were higher in the clonal and reactive thrombocytosis groups than in controls (p<0.05), indicating a thrombotic tendency. Shortened prothrombin time and activated thromboplastin time are other signs of increased procoagulant activity. Thromboses may develop in different sites of venous and arterial systems, including cerebral arteries and sinus veins, portal system veins, coronary arteries, and lower limbs vessels (1, 25, 26) .
Many attempts have been made to use clinical laboratory tests to predict which patients with thrombocytosis are prone to the risk of thrombosis; however, most studies have failed to identify these patients by the use of platelet function tests (27, 28) . Platelet abnormalities that could explain thrombotic complications, such as increased beta-thromboglobulin and platelet factor 4 levels (28) (29) (30) , and platelet activation (31), have been described. It is possible that the fibrinolytic system may be activated or, better still, inhibited. Elevated plasminogen activator inhibitor-1 (PAI-1) levels characterized by defective fibrinolysis (32) (33) (34) are reported to be involved in the pathogenesis of both arterial and venous thrombosis.
Because of its antifibrinolytic effect, TAFI might be implicated in thrombotic diseases. Studies with animal and human models have suggested that TAFI contributes to the hypofibrinolysis observed in venous thrombosis (35) (36) (37) . Contradictory results regarding TAFI levels and coronary artery disease have been reported. An increase in TAFI activation in patients with coronary artery disease has been observed when compared with control individuals (38) , and a high TAFI antigen level was found to be a risk factor by some authors (39) , and a protective factor by others (40) .
Increased TAFI activity was also reported in the intraalveolar space of patients with interstitial lung disease (41) , and in the plasma of dialyzed diabetic patients (42) , suggesting that TAFI activity might play important roles in the mechanism of impaired fibrinolysis in these patients. On the other hand, Antovic and colleagues (43) have reported that TAFI did not influence either fibrinolysis or the increased thrombotic potential observed in patients with type I diabetes mellitus.
In cirrhotic patients plasma levels of TAFI antigen were found to be reduced, most likely because of impaired synthesis (44, 45) . Plasma clots from cirrhotic patients were reported to be more susceptible to fibrinolysis induced by a physiological concentration of exogenous tissue plasminogen activator than control clots, in which TAFI deficiency was found to be the main cause of hyperfibrinolysis (46) .
To our knowledge, changes in the activity of TAFI have not previously been studied in patients with thrombocytosis. In this study we observed significantly elevated TAFI activation in patients with clonal thrombocytosis. Hypofibrinolysis due to increased TAFI activity in the clonal thrombocytosis group can better explain the thrombotic tendency in this group of patients than in patients with secondary thrombocytosis.
In conclusion, our study confirms that hypofibrinolysis due to increased TAFI activation in clonal thrombocytosis can also be considered a factor to explain the thrombotic tendency in myeloproliferative disorders and can help select patients who might benefit from antithrombotic treatment.
